The Vox Markets Podcast
/
Jeremy Skillington of Poolbeg Pharma discusses their Nasdaq partnership for development of an optimised oral drug to treat a metabolic condition
Our new player has been redesigned to fit in better wherever you embed it. Feedback is welcome on our support site.
You can still use our old player if you prefer.